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Gender analysis of the pivotal results of the
Medtronic Talent Thoracic Stent Graft System
(VALOR) trial
Benjamin M. Jackson, MD,a Edward Y. Woo, MD,a Joseph E. Bavaria, MD,b and
Ronald M. Fairman, MD,a Philadelphia, Pa
Purpose: This study evaluated the differences between male and female patients undergoing thoracic endovascular
aneurysm repair (TEVAR) in a pivotal Food and Drug Administration (FDA)-approved trial.
Methods: The Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic
Aortic Aneurysms (VALOR) study was a prospective, nonrandomized, multicenter, pivotal trial conducted in the United
States. Patients were enrolled between December 2003 and June 2005. Follow-up was conducted at 30 and 365 days.
Results: VALOR enrolled 115 men (58.9%; 69.3  11.7 years old), and 80 women (41.1%; 71.6  10.1 years old). Iliac
conduits were used more often in women, who had smaller diameter external iliac arteries, than in men (38.8% vs 8.8%,
P < .001). Women required more blood transfusions and had a longer hospital length of stay. At 30 days, more major
adverse events occurred in women than in men (52.5% vs 33.0%, P  .008), with more vascular access-related and
respiratory complications. No gender-based differences were seen in all-cause mortality or in aneurysm-related death. The
composite end point of 365-day “successful aneurysm treatment,” defined as no aneurysm growth>5 mm at the 365-day
follow-up visit compared with the 30-day follow-up visit and absence of any type I endoleak requiring a secondary
procedure, favored women over men (98.2% vs 82.4%, P  .004).
Conclusions: TEVAR with the Talent device provided similar rates of 365-day mortality and morbidity for men and
women. Although female patients had higher rates of periprocedural complications, they also more often had successful
aneurysm treatment at the 1-year follow-up. (J Vasc Surg 2011;54:358-63.)
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EIn series of endovascular repair (EVAR) of abdominal
aortic aneurysms (AAAs), the ratio of men to women
undergoing repair is between 4:1 and 5:1.1 In contrast, in
series of patients undergoing thoracic endovascular repair
(TEVAR) for thoracic aortic aneurysms (TAA), the ratio of
men to women is between 1:1 and 3:1.2,3 Therefore, as the
U.S. Food and Drug Administration (FDA) evaluates and
approves thoracic stent graft devices, it is important to
evaluate their safety and efficacy in female patients specifi-
cally. Because women have smaller iliac and femoral arter-
ies, and smaller normal-diameter aortas, device sizing and
delivery system size may contribute to differing outcomes
between the genders.
The Evaluation of the Medtronic Vascular Talent Tho-
racic Stent Graft System for the Treatment of Thoracic
Aortic Aneurysms (VALOR) study was a prospective, non-
randomized, multicenter, pivotal trial conducted at 38 sites
to evaluate the 30-day and 365-day results of endovascular
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358reatment using the Medtronic Vascular Talent Thoracic
tent Graft System (Medtronic Vascular, Santa Rosa, Calif)
n patients with TAAs who were considered candidates for
pen surgical repair with low to moderate surgical risk.4
he results were compared with retrospective open tho-
acic aneurysm repairs on 189 patients at three centers of
xcellence. The trial enrolled 195 patients. Compared with
atients undergoing open surgery, patients undergoing
EVAR benefitted with respect to acute procedural out-
omes, 30-day major adverse events (MAEs; 41% vs 84.4%,
 .001), perioperative mortality (2% vs 8%, P .01), and
65-day aneurysm-related mortality (3.1% vs 11.6%, P 
002).4
This report addresses differences in the procedural re-
ults and primary outcome measures between the 115 male
nd 80 female VALOR patients to assess whether gender
ffects the safety and efficacy of TEVAR or the performance
f the Talent device; as such, new data and conclusions are
resented.
ETHODS
Patient selection in the VALOR trial. The VALOR
rial was a prospective, nonrandomized, multicenter clinical
tudy conducted in the United States to evaluate the safety
nd efficacy of the Medtronic Vascular Talent Thoracic
tent Graft System in the treatment of aneurysmal disease
f the descending thoracic aorta. Enrollment occurred
etween December 2003 and June 2005 at 38 institutions.
nrolled patients were diagnosed with TAA and were con-
idered candidates for open surgical repair with low to
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Volume 54, Number 2 Jackson et al 359moderate risk according to the modified criteria of the
Society for Vascular Surgery and the American Association
for Vascular Surgery.5 Anatomic and medical inclusion and
exclusion criteria were identical with the original report of
the pivotal trial.4 The VALOR trial was approved by the
FDA and site Institutional Review Boards. Patients signed
an informed consent before participation in the investiga-
tional study.
Technique and device description. During VALOR
trial enrollment, the Talent device consisted of a modular
preloaded stent graft and the CoilTrac delivery system
(Medtronic Vascular). The implanted endoprosthetic portion
of the Talent system is composed of a polyester graft fabric
sewn to a self-expanding nickel-titanium wire frame. Catalog
and custom stent graft configurations were available for the
VALOR trial. Stent graft oversizing of 2 to 4 mm relative to
the native aortic diameter (measured as adventitia to adventi-
tia)was recommended to provide the necessary outward radial
force tomaintain stent graft apposition against the aortic wall.
The VALOR trial required a minimum overlap of 30 mm
for multiple stent grafts. The Reliant balloon catheter
(Medtronic) was used at the discretion of the physician to
expand the stent graft against the aortic wall and in overlap
regions. Adjunctive surgical techniques, including iliac artery
conduits, spinal drains, and left subclavian artery revasculariza-
tion, were left to the surgeons’ discretion.
Standard follow-up evaluations were performed at 30,
180, and 365 days. Follow-up visits included a computed
tomography (CT) scan, chest radiograph, and physical exam-
ination. All clinical data were reported by the investigative
center on case report forms andmonitored byMedtronic, the
sponsor of the study. A clinical events committee adjudicated
MAEs for their relationship to the device or the procedure.
M2S (West Lebanon, NH) served as the imaging core labo-
ratory and provided data evaluation of all imaging studies,
ensuring third-party assessment of graft effectiveness.
Subsequent to FDA review of the VALOR trial, the
Talent Thoracic Stent Graft System was approved in June
2008.
End points and definitions. The primary safety end
point of the VALOR trial was all-cause mortality at 365
days. The primary effectiveness end point, successful aneu-
rysm treatment, was a composite consisting of two out-
comes: (1) no aneurysm growth 5 mm at the 365-day
follow-up visit compared with the 30-day follow-up visit;
and (2) absence of any type I endoleak requiring a second-
ary procedure performed before, during, or as a result of the
evaluation at the 365-day follow-up visit.
An MAE was defined as death due to the procedure,
any death within 30 days of the procedure, respiratory
complications, renal insufficiency or failure, a cardiac event,
a neurologic event, aneurysm rupture, bowel ischemia,
major bleeding, or vascular complications. Endoleaks were
defined according to the well-established type I to IV
nomenclature.6 Migration was defined as 10 mm proxi-
mal or distal movement of the stent graft relative to fixed
anatomic landmarks. Aneurysm expansion was defined as a
5-mm increase in diameter between the 1-month and W2-month follow-up visits. Aneurysm-related death was
efined as any death30 days from the initial implantation
r occurring as a consequence of an aneurysm rupture, a
onversion to open repair, or any other secondary endovas-
ular procedure associated with the aneurysm that was
reated by the Talent device, as evidenced by CT scan,
ngiography, or direct observation at surgery or autopsy.
Statistical analysis. For categoric variables, the number
n each category and the percentage of known values are
rovided; unless otherwise indicated, P values were calculated
sing 2 tests. For continuous variables, the mean and stan-
ard deviation are provided; for some parameters the median
alues are also provided. Unless otherwise indicated, t tests
ere used to assess gender-dependence of continuous vari-
bles, andWilcoxon rank sum testswere used for nonparamet-
ic continuous variables. Kaplan-Meier analysis was used to
escribe freedom fromadverse events over time.Values ofP
05 were considered significant.
ESULTS
Preoperative characteristics. The 195 patients en-
olled in the VALOR trial consisted of 115 men (58.9%)
nd 80 women (41.1%). Baseline medical history for the
ntire cohort has been reported previously.4 With respect
o pre-existing conditions and medical history, there were
o statistically significant differences between male and
emale cohorts. Similarly, there were no differences be-
ween male and female patients in baseline anatomic char-
cteristics or symptomatic status (Table I). Aneurysm
ength and maximal diameter did not differ between male
nd female patients, but proximal and distal neck diameters
nd bilateral external iliac diameters were all significantly
maller in female patients than in male patients (Table II).
Procedure and hospital course. Deployment of the
tudy device at the intended site was successful in 194
atients (99.5%); the exception was a patient who did not
eceive a device because of access failure. Notably, that
atient was a man. Iliac conduits were required more
requently in women than men (38.8% vs 8.8%, P .001).
able I. Aneurysm anatomy and symptoms
ariable
Male Female
Pa
(n  115) (n  80)
% (No) % (No)
usiform TAA 54.8 (63) 61.3 (49) .381
accular/penetrating ulcer TAA 38.3 (44) 32.5 (26) .450
usiform  saccular/penetrating
ulcer TAA 7.0 (8) 6.3 (5) .99
neurysm symptoms 26.1 (30) 26.3 (21) .99
Pain 13.0 (15) 20.0 (16) .233
Nausea 1.7 (2) 1.3 (1) .99
Chest pain 13.0 (15) 13.8 (11) .99
Hoarseness 2.6 (3) 3.8 (3) .691
Abdominal pain 1.7 (2) 5.0 (4) .230
Other 6.1 (7) 6.3 (5) .99
AA, Thoracic aortic aneurysm.
Fisher exact test.omen more frequently required a blood transfusion and
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August 2011360 Jackson et alhad a greater mean volume of blood loss than men. Proce-
dural variables are summarized in Table III. Although
intensive care unit length of stay was not significantly
different for women (59.8  153.4 hours) than men
(37.8  75.8 hours, P  .515), the overall hospital length
of stay was significantly longer for women (9.0 16.2 days
vs 4.7  5.8 days, P  .001).
With regard to devices used, a clear trend was noted
toward implantation in men of larger-diameter grafts and
toward implantation in women of the smallest grafts. Fifteen
46-mm proximal main devices were used in the trial, of which
14 were implanted in men; meanwhile, of the four 22-mm
and24-mmproximalmain devices used, threewere implanted
in women. Nevertheless, no significant difference was de-
tected with respect to proximal graft oversizing (Table III).
Safety and efficacy. There was no difference between
male and female patients with respect to all-cause mortality
at 30 days or 365 days (Fig, Table IV), nor was there any
difference with respect to aneurysm-related mortality at
365 days by log-rank (P  .71) or Fisher exact (P  .84)
tests. The primary effectiveness end point, successful aneu-
rysm treatment at 365 days, was significantly higher in
women than in men (98.2% vs 82.4%, P  .004): women
were less likely than men to have a change in maximum
aneurysm diameter of 5 mm between 30 and 365 days
(1.8% vs 13.7%, P  .023).
At 30 days, significantly fewer MAEs occurred in men
than in women (33.0% vs 52.5%, P  .008). Accounting
for this difference, vascular complications (13.9% vs
36.3%, P  .001) and respiratory complications (7.8% vs
21.3%, P  .009) were less common in men than in
women. Of note, no correlation was detected between
vascular complication incidence and vessel size. Other
MAEs are summarized in Table V.
DISCUSSION
These results from the pivotal VALOR trial of the
Talent thoracic stent graft indicate that TAA repair in
women is at least as effective as in men. In the 365-day
Table II. Preoperative core laboratory vessel dimensions
Variable
Male Female
Pa
(n  109) (n  78)
Mean  SD,
mm
Mean  SD,
mm
Proximal neck diameter 32.4  4.9 29.5  4.4 .001
Maximum aneurysm
diameter 55.7  11.7 55.2  11.6 .533
Distal neck diameter 30.5  5.3 28.6  4.4 .014
Aneurysm length 123.5  73.7 118.4  71.5 .590
(n  71) (n  53)
Minimum diameter
Right external iliaca 7.1  1.4 5.7  1.3 .001
Left external iliaca 7.3  1.4 5.7  1.3 .001
aWilcoxon rank sum test.composite measure “successful aneurysm treatment,” fe- 1ale patients fared better than male patients (98.2% vs
2.4%). From the current data, it is unclear whether this
ill result in improved aneurysm-free survival in the long
erm; 1-year survival in the current data demonstrates no
ifference in overall mortality. Although one might guess
hat the higher “successful aneurysm treatment” rate in
omen might be due to smaller necks—and hence more
ikely proximal seal—the percentage of oversizing was sim-
lar between genders.
Complications were more commonly seen in women in
he trial, however. Women had more frequent MAEs and
ad greater blood loss and more frequent transfusion re-
uirements. Given that the difference in MAEs was largely
ue to more frequent vascular complications and—in
articular—more frequent “vessel disruption,” it seems
ogical that much of the increased blood loss, complication
isk, and transfusion requirement resulted from the smaller
ccess vessels in women. The lack of correlation detected
etween vascular complication incidence and vessel size was
ikely due to lack of power in the study to detect the
orrelation and to the confounding element of conduit
tilization.
Other published experiences with the Talent device
ave not always demonstrated such high rates of access
njury.7 However, as a prospective pivotal trial, the report-
ng in this study is verifiable, and the results highlight the
act that access-related complications or failure are a real
isk in TEVAR. Of note, the delivery system used for the
alent endograft in the VALOR trial was a previous gener-
tion system. More recent delivery systems from various
anufacturers, including Medtronic, have incorporated
ydrophilic sheaths, among other improvements.
The observed higher rate of respiratory complications
n womenmight be due to any number of factors, including
ifferences in resuscitation (crystalloid and transfusion
roducts) and differences in predisposing degrees of
hronic lung disease. This difference in respiratory compli-
ations is constituted largely in a higher rate of pneumonia
n women than men.
A disadvantage of all currently available thoracic stent
rafts is their large-diameter delivery systems. Depending
n device diameter, the delivery system catheter outside
iameter ranges from 22F to 25F for Talent grafts. The
ore treacherous vascular access in women may be miti-
ated by frequent use of adjunctive access procedures, such
s conduit creation. In the current trial, conduits were used
hree times more frequently in women than in men. Other
tudies have reported a similar overall rate of use of con-
uits.8
A prior study conducted to determine the anatomic
arriers to TEVAR for TAA evaluated 126 patients (73
en and 53 women) with isolated TAA. Of this total, 33
26%) were rejected for TEVAR on anatomic grounds.9
he rejected patients were generally older (70 years) and
ad aneurysms of significant size (6.4  1.4 cm), and they
ere excluded for more than one criterion. However, re-
ection was not significantly different by gender (16 men vs
7 women, P  .22). There were also no gender-based
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proximal necks, hostile distal necks, or both. More of the
rejected female patients had difficult access anatomy, but
the difference was not significant.
This gender analysis of the results of the pivotal
VALOR trial represents the most extensive examination to
Table III. Details of procedures
Procedural details (
LSA revascularization before initial procedure 5
Iliac conduit 8
Study devices implanted per subject
Subjects requiring blood transfusion 15
Blood loss during procedure, mL 2
Duration of implant procedure, min 14
Volume of contrast used, mL 16
Proximal oversizing
10% 14
10%-20% 40
20% 44
LSA, Left subclavian artery.
Categoric data are presented as percentage (number) and continuous data a
aUnless otherwise noted.
bFisher exact test.
c2 test.
dWilcoxon rank sum test.
Fig. Kaplan-Meier plot of freedom from all-cause mortal
trial.date of differences between male and female patients in cesponse to TEVAR. Several studies have suggested that
ale patients with AAA are younger and possibly have
etter outcomes than female patients.10,11 In a large cohort
tudy of 12,917 AAA patients treated with open or endo-
ascular repair, gender was not associated with differences
n mortality rates, but aneurysm-related death was more
le Female
P14)a (n  80)a
5.0 (4) .99b
) 38.8 (31) .001b
1.4 2.6  1.2 .350c
) 32.5 (26) .009b
407 516  611 .001d
72.2 173.3  77.7 .001d
91.7 137.4  79.7 .028d
.125b
/110) 15.4 (12/78)
/110) 26.9 (21/78)
/110) 57.7 (45/78)
n  standard deviation.
365 days for male and female participants in the VALORMa
n  1
.3 (6)
.8 (10
2.8 
.8 (18
69 
0.7 
3.9 
.5 (16
.9 (45
.5 (49
s meaity atommon in female than in male patients.12 The investiga-
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August 2011362 Jackson et altors speculated that this result might actually be due to
untreated TAA, noting that in women, TAAmight bemore
equally distributed than AAA.
Gender differences—with regard to anatomic features
and suitability for endografting at least—have been exam-
ined for AAAs. A study by Velazquez et al13 demonstrated
that smaller iliac arteries and shorter, more angulated prox-
imal necks might limit applicability of EVAR in women
Table IV. Safety and efficacy
Variable
All-cause mortality
30 days
At 365 days
Aneurysm-related death 365 days
Paralysis at 30 days
Paraparesis at 30 days
Successful aneurysm treatment at 365 days
Change in aneurysm diameter 5 mm between 30 and 365 days
Secondary endovascular endoleak repair
Conversion to open surgical repair
Aneurysm rupture
Migration of stent graft 10 mm
Endoleaks
Type I
Type II
Type III
Indeterminate
aUnless noted otherwise.
bFisher exact test.
Table V. Major adverse events at 30 days
Event
Male Female
Pa
(n  115) (n  80)
% (No.) % (No.)
Respiratory complications 7.8 (9) 21.3 (17) .009
Pneumonia 5.2 (6) 15.0 (12) .025
Pulmonary embolism 0.9 (1) 0 (0) .99
Respiratory failure 3.5 (4) 10.0 (8) .074
Renal insufficiency or failure 7.0 (8) 5.0 (4) .764
Myocardial infarction 1.7 (2) 1.3 (1) .99
Neurologic complications 8.7 (10) 16.3 (13) .119
Stroke 1.7 (2) 6.3 (5) .125
Paraplegia 0.9 (1) 2.5 (2) .569
Paraparesis 6.1 (7) 8.8 (7) .576
Bowel ischemia 0.9 (1) 1.3 (1) .99
Vascular complications 13.9 (16) 36.3 (29) .001
Expanding hematoma at access
site 2.6 (3) 0 (0) .270
Pseudoaneurysm at access site 0.9 (1) 3.8 (3) .307
Retroperitoneal bleed 1.7 (2) 3.8 (3) .402
Arterial occlusion 0.9 (1) 3.8 (3) .307
Vessel rupture/dissection 7.0 (8) 5.0 (4) .764
Vessel disruption 1.7 (2) 16.3 (13) .001
Embolism 2.6 (3) 8.8 (7) .095
Reoperation for limb ischemia 0.9 (1) 1.3 (1) .99
Total major adverse events 33.0 (38) 52.5 (42) .008
aFisher exact test.compared with men. The current study similarly demon- ctrates smaller external iliac arteries and smaller proximal
nd distal neck diameter, but no evidence of shorter prox-
mal necks in TAAs in women relative to men. Meanwhile,
ome investigators have demonstrated more frequent
ccess-related complications in women than in men under-
oing EVAR.14,15
Although the Talent TEVAR experience summarized
ere does not include an examination of gender-based
ifferences in exclusion fromTAA repair, other studies have
ddressed this issue for both TEVAR and EVAR. In partic-
lar, Moise et al16 demonstrated that women were more
ikely than men to be excluded from EVAR because of
natomic features. However, the same group did not find
ny female predilection toward anatomic rejection for TE-
AR during pivotal stent graft trials performed at a single
nstitution.9 Clearly, design of future-generation thoracic
tent grafts will require attention to the requirements in-
erent in treating women.
An advantage of the Talent device is the wide range of
iameters: from 22 to 46 mm for treatment of aortic
iameters from 18 to 42 mm. TEVAR in younger
atients—for example, those with aortic transection—and
n women may be facilitated with the smaller devices.
upporting this supposition, female patients in the current
tudy had smaller diameter proximal and distal necks, and
n three women (compared with only one man) 22-mm or
4-mm proximal main grafts were implanted.
ONCLUSIONS
The gender analysis of the pivotal VALOR trial suggests
hat women with aneurysms of the descending thoracic aorta
ay be treated as successfully asmenwith the Talent Thoracic
tentGraft System. Female patients undergoingTEVARwith
his device, however, did have higher rates of periprocedural
Male Female
Pb
(n  115)a (n  80)a
% (No.) % (No.)
1.7 (2) 2.5 (2) .99
16.8 (19/113) 15.2 (12/79) .843
2.7 (3/113) 3.8 (3/79) .691
0.9 (1/115) 2.5 (2) .569
6.1 (7) 8.8 (7) .576
82.4 (61/74) 98.2 (55/56) .004
13.7 (10/73) 1.8 (1/56) .023
6.4 (7/109) 5.2 (4/77) .99
0.9 (1/112) 0 (0) .99
0 (0/112) 1.3 (1) .417
3.4 (2/58) 4.4 (2/45) .99
15.9 (11/69) 7.4 (4/54) .176
4.3 (3/69) 5.6 (3/54) .99
7.2 (5/69) 1.9 (1/54) .228
0 (0/69) 0 (0/54) —
4.3 (3/69) 0 (0/54) —omplications and 30-day MAEs, especially vascular compli-
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Volume 54, Number 2 Jackson et al 363cations, and the surgeon must remain cognizant of both
delivery system size and access vessel diameter.
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In addition to the authors of this article, the following
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